| (Values in U.S. Thousands) | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2025 | Dec, 2025 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -32,070 | -480 | 0 | 0 | 0 |
| Net Income Growth | -6,581.26% | unch | unch | unch | unch |
Apexigen Inc WT (APGNW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Apexigen Inc. is a clinical-stage biopharmaceutical company. It focused on discovering and developing a new generation of antibody therapeutics for oncology. Apexigen Inc., formerly known as Brookline Capital Acquisition Corp., is based in SAN CARLOS, Calif.
Fiscal Year End Date: 12/31